Sangamo BioSciences announces evidence of HIV functional control with SB-728-T


Sangamo BioSciences (SGMO) presents what it says is "the first evidence that sustained functional control of HIV in the absence of antiretroviral therapy is possible."

The company says viral load became undetectable during an ART treatment interruption in three of seven patients treated with SB-728-T.

In one patient, viral load has been undetectable for seven weeks.

The company calls this "a major step toward immunological functional control of HIV." (PR)

SGMO +3.2% AH

From other sites
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Hub
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs